Immunoproteomic analysis of a Chikungunya poxvirus-based vaccine reveals high HLA class II immunoprevalence

PLoS Negl Trop Dis. 2019 Jul 5;13(7):e0007547. doi: 10.1371/journal.pntd.0007547. eCollection 2019 Jul.

Abstract

Background: Efficient adaptive antiviral cellular and humoral immune responses require previous recognition of viral antigenic peptides bound to human leukocyte antigen (HLA) class I and II molecules, which are exposed on the surface of infected and antigen presenting cells, respectively. The HLA-restricted immune response to Chikungunya virus (CHIKV), a mosquito-borne Alphavirus of the Togaviridae family responsible for severe chronic polyarthralgia and polyarthritis, is largely unknown.

Methodology/principal findings: In this study, a high-throughput mass spectrometry analysis of complex HLA-bound peptide pools isolated from large amounts of human cells infected with a vaccinia virus (VACV) recombinant expressing CHIKV structural proteins was carried out. Twelve viral ligands from the CHIKV polyprotein naturally presented by different HLA-A, -B, and -C class I, and HLA-DR and -DP class II molecules were identified.

Conclusions/significance: The immunoprevalence of the HLA class II but not the HLA class I-restricted cellular immune response against the CHIKV structural polyprotein was greater than that against the VACV vector itself. In addition, most of the CHIKV HLA class I and II ligands detected by mass spectrometry are not conserved compared to its closely related O'nyong-nyong virus. These findings have clear implications for analysis of both cytotoxic and helper immune responses against CHIKV as well as for the future studies focused in the exacerbated T helper response linked to chronic musculoskeletal disorders in CHIKV patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Genetically Modified
  • Antigen Presentation
  • Antigen-Presenting Cells / immunology
  • Chikungunya Fever / immunology
  • Chikungunya Fever / prevention & control*
  • Chikungunya virus
  • Histocompatibility Antigens Class II / immunology*
  • Humans
  • Immunity, Cellular
  • Immunogenicity, Vaccine
  • Mass Spectrometry
  • Mice
  • Proteomics*
  • T-Lymphocytes, Cytotoxic / immunology
  • T-Lymphocytes, Helper-Inducer / immunology
  • Vaccinia virus*
  • Viral Proteins / immunology*
  • Viral Vaccines / genetics
  • Viral Vaccines / immunology*

Substances

  • Histocompatibility Antigens Class II
  • Viral Proteins
  • Viral Vaccines

Grants and funding

This work was supported by the Spanish Ministry of Economy grants SAF2014-58052 and “Acción Estratégica en Salud” 2018 to DL, SAF-2013-45232-R and SAF-2017-88089-R to ME, and by Israel Science Foundation, grant No. 1435/16 to AA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.